Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-Year study results

Canadian Journal of Ophthalmology

Volumn 47, Issue 1, 2012, Pages 28-33

  Peiretti, Enrico ^a   Vinci, Michela ^a   Fossarello, Maurizio ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG ADMINISTRATION ROUTE; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; LONG TERM CARE; MALE; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84857347319     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2011.12.009     Document Type: Article

References (25)

1. Ghafour IM, Allan D, Foulds WS. Common causes of blindness and visual handicap in the west of Scotland. Br J Ophthalmol. 1983;67:209-13. (Pubitemid 13114741)
2. Curtin BJ. The nature of pathologic myopia. In: Curtin BJ, ed. The Myopias. Harper & Row, Philadelphia, PA.; 1985:237-45.
3. Steidl SM, Pruett RC. Macular complications associated with posterior staphyloma. Am J Ophthalmol. 1997;123:181-7. (Pubitemid 27066773)
4. Noble KG, Carr RE. Pathologic myopia. Ophthalmology. 1982;89:1099-100. (Pubitemid 12001642)
5. Hayasaka S, Uchida M, Setogawa T. Subretinal hemorrhages with or without choroidal neovascularization in the macula of patients with pathologic myopia. Graefes Arch Clin Exp Ophthalmol. 1990;228:277-80. (Pubitemid 20211856)
6. Hotchkiss ML, Fine SL. Pathologic myopia and choroidal neovascularization. Am J Ophthalmol. 1981;91:177-83. (Pubitemid 11184477)
7. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology. 1984;91:1573-81. (Pubitemid 15197032)
8. Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology. 1983;90:923-6. (Pubitemid 13004305)
9. Grossniklaus HE, Green WR. Pathologic findings in pathologic myopia. Retina. 1992;12:127-33.
10. Levy JH, Pollock HM, Curtin BJ. The Fuchs' spot: an ophthalmoscopic and fluorescein angiographic study. Ann Ophthalmol. 1977;9:1433-43. (Pubitemid 8247141)
11. Tabandeh H, Flynn HW Jr, Scott IU, et al. Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology. 1999;106:2063-7. (Pubitemid 30194225)
12. Yoshida T, Ohno-Matsui K, Ohtake Y, et al. Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups. Ophthalmology. 2002;109:712-9. (Pubitemid 34270128)
13. Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a 10- year follow-up. Ophthalmology. 2003;110:1297-305. (Pubitemid 36842462)
14. Chan WM, Ohji M, Lai TY, Liu DT, Tano Y, Lam DS. Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol. 2005;89:1522-8. (Pubitemid 41527394)
15. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial - VIP report no. 1. Ophthalmology. 2001;108:841-52.
16. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP report no. 3. Ophthalmology. 2003;110:667-73. (Pubitemid 36520061)
17. Chan WM, Lai TY, Wong AL, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathologic myopia: a pilot study. Br J Ophthalmol. 2007;91:174-9. (Pubitemid 46202864)
18. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathological myopia. Br J Ophthalmol. 2007;91:161-5. (Pubitemid 46202863)
19. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathological myopia. Br J Ophthalmol. 2007;91:157-60. (Pubitemid 46202862)
20. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology. 2007;114:2190-6.
21. Ikuno Y, Sayanagi K, Soga K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol. 2009;147:94-100.
22. Chan WM, Lai TYY, Liu DTL, Lam DSC. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization:1-year results of a prospective study. Br J Ophthalmol. 2009;93:150-4.
23. Ruiz-Moreno JM, Montero JA. Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefes Arch Clin Exp Ophthalmol. 2010;248:937-41.
24. Hayashi K, Ohno-Matsui K, Teramukai S, et al. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol. 2009;148:396-408.
25. Baba T, Kubota-Taniai M, Kitahashi M, Okada K, Mitamura Y, Yamamoto S. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularization. Br J Ophthalmol. 2010;94:864-70.